Print page |
E-mail page
| 
Download PDF
« Previous Release | Next Release »
Shareholders of Harris & Harris Group, Inc., may be interested to know that Metabolon's biochemical profiling technology has been used to identify biomarkers indicative of prostate cancer progression. The results of the study will be published in the February 12, 2009, issue of Nature in a paper titled "Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression." The study described in the Nature paper was undertaken to better understand and profile the metabolic changes associated with prostate cancer progression. Using Metabolon's biochemical profiling to generate global, non-targeted metabolic analysis of tissue, urine and plasma samples, the researchers were able to identify a series of metabolites (including sarcosine) that are key potential predictors of cancer aggressiveness. Metabolon's press release can be accessed at http://www.metabolon.com/news/.
Harris & Harris Group is an investor in privately held Metabolon, Inc.
Harris & Harris Group is a publicly traded venture capital company that invests in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). A growing percentage of the Company's portfolio consists of companies developing cleantech solutions.
Detailed information about Harris & Harris Group and its holdings can be found on its website at www.TinyTechVC.com.
This news release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this news release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, the Company's report on Form 10-Q for the quarter ended September 30, 2008 and subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc., undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The reference to the websites www.TinyTechVC.com and www.metabolon.com has been provided as a convenience, and the information contained on such websites is not incorporated by reference into this news release. Harris & Harris Group is not responsible for the contents of third party websites.
CONTACT:
DOUGLAS W. JAMISON
TEL. NO. (212) 582-0900